If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Clinical trials

Training Experience

1995Internship, Mount Sinai Hospital, New York
1996Residency, Mount Sinai Hospital, New York

Education/Academic qualification

MD, University La Sapienza, Rome, Italy

… → 1988


  • Blood Cancer (leukemia and lymphomas)
  • Clinical Research

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 15 Similar Profiles
Peripheral T-Cell Lymphoma Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2006 2021

Research Output 2000 2019

12 Citations (Scopus)

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

ECHELON-2 Study Group, Jan 19 2019, In : The Lancet. 393, 10168, p. 229-240 12 p.

Research output: Contribution to journalArticle

Peripheral T-Cell Lymphoma
Drug Therapy

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

Khashab, T., Hagemeister, F., Romaguera, J. E., Fanale, M. A., Pro, B., McLaughlin, P., Rodriguez, M. A., Neelapu, S. S., Fayad, L., Younes, A., Feng, L., Vega, F., Kwak, L. W. & Samaniego, F., Jan 1 2019, In : British Journal of Haematology.

Research output: Contribution to journalArticle

Non-Hodgkin's Lymphoma
Disease-Free Survival
Survival Rate

Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy

Mina, A. A., Vakkalagadda, C. & Pro, B., Mar 1 2019, In : Cancers. 11, 3, 421.

Research output: Contribution to journalReview article

Open Access
Hodgkin Disease
Salvage Therapy
Drug Therapy
Stem Cells

Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry

Stuver, R. N., Khan, N., Schwartz, M., Acosta, M., Federico, M., Gisselbrecht, C., Horwitz, S. M., Lansigan, F., Pinter-Brown, L. C., Pro, B., Shustov, A. R., Foss, F. M. & Jain, S., Jun 1 2019, In : American Journal of Hematology. 94, 6, p. 641-649 9 p.

Research output: Contribution to journalArticle

Peripheral T-Cell Lymphoma
Combination Drug Therapy

The histological prevalence and clinical implications of folliculotropism and syringotropism in mycosis fungoides

Hossain, C., Jennings, T., Duffy, R., Knoblauch, K., Gochoco, A., Chervoneva, I., Shi, W., Alpdogan, S. O., Porcu, P., Pro, B. & Sahu, J., Feb 1 2019, In : Chinese clinical oncology. 8, 1, 1 p.

Research output: Contribution to journalArticle

Mycosis Fungoides
Cutaneous T-Cell Lymphoma
Sweat Glands